We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Dexcom's (DXCM) Digital Network Benefits From Latest FDA Nod
Read MoreHide Full Article
DexCom, Inc. (DXCM - Free Report) recently announced the receipt of the FDA’s clearance for Dexcom Partner Web APIs. The latest nod will enable approved third-party developers to integrate real-time continuous glucose monitoring (“CGM”) data into their digital health apps and devices.
For investors’ note, various renowned diabetes and digital health players have been invited to access the real-time APIs. Many are already in the testing and development phase, including Garmin Ltd. (GRMN - Free Report) and Teladoc Health, Inc.’s (TDOC - Free Report) Livongo for Diabetes.
With the latest regulatory clearance, Dexcom is expected to solidify its foothold in the global CGM business.
Significance of the Clearance
Per management, the FDA’s approval of its real-time APIs provides Dexcom users a wider choice of viewing and interacting with their glucose data. The new APIs will aid in seamlessly integrating the real-time Dexcom CGM data into some of the leading diabetes and digital health solutions.
The clearance expands connectivity and interoperability of the Dexcom CGM digital ecosystem. It also allows invited third-party developers to connect applications and devices to real-time CGM data.
Industry Prospects
Per a report by Grand View Research, the global CGM device market size was valued at $3,929.7 million in 2019 and is expected to reach $10.4 billion by 2027 at a CAGR of 12.7%. Factors like rising cases of diabetes and increasing adoption of CGM devices are likely to drive the market.
Given the market potential, the latest FDA approval is expected to provide a significant boost to Dexcom’s business globally.
Notable Developments
Of late, Dexcom has witnessed a few notable developments across its business.
The company, in June, announced that the Dexcom G6 CGM system might now be eligible for provincial coverage through BC PharmaCare. Diabetics who are on intensive insulin therapy and above the age of two, maybe entitled to the coverage.
The same month, Dexcom announced that people with diabetes below the age of 18 living in Saskatchewan, Canada may now receive provincial coverage for the Dexcom G6 CGM System through Saskatchewan Health.
In May, the company announced that people with type 1 diabetes above the age of two may now receive provincial coverage for the Dexcom G6 CGM System by the Régie de l'Assurance Maladie du Quebec.
Price Performance
Shares of the company have gained 3.8% in the past year compared with the industry’s 12.5% growth and the S&P 500's 34.6% rise.
Image Source: Zacks Investment Research
Zacks Rank & Stock to Consider
Currently, Dexcom carries a Zacks Rank #5 (Strong Sell).
A better-ranked stock from the broader medical space is Veeva Systems Inc. (VEEV - Free Report) .
Image: Bigstock
Dexcom's (DXCM) Digital Network Benefits From Latest FDA Nod
DexCom, Inc. (DXCM - Free Report) recently announced the receipt of the FDA’s clearance for Dexcom Partner Web APIs. The latest nod will enable approved third-party developers to integrate real-time continuous glucose monitoring (“CGM”) data into their digital health apps and devices.
For investors’ note, various renowned diabetes and digital health players have been invited to access the real-time APIs. Many are already in the testing and development phase, including Garmin Ltd. (GRMN - Free Report) and Teladoc Health, Inc.’s (TDOC - Free Report) Livongo for Diabetes.
With the latest regulatory clearance, Dexcom is expected to solidify its foothold in the global CGM business.
Significance of the Clearance
Per management, the FDA’s approval of its real-time APIs provides Dexcom users a wider choice of viewing and interacting with their glucose data. The new APIs will aid in seamlessly integrating the real-time Dexcom CGM data into some of the leading diabetes and digital health solutions.
The clearance expands connectivity and interoperability of the Dexcom CGM digital ecosystem. It also allows invited third-party developers to connect applications and devices to real-time CGM data.
Industry Prospects
Per a report by Grand View Research, the global CGM device market size was valued at $3,929.7 million in 2019 and is expected to reach $10.4 billion by 2027 at a CAGR of 12.7%. Factors like rising cases of diabetes and increasing adoption of CGM devices are likely to drive the market.
Given the market potential, the latest FDA approval is expected to provide a significant boost to Dexcom’s business globally.
Notable Developments
Of late, Dexcom has witnessed a few notable developments across its business.
The company, in June, announced that the Dexcom G6 CGM system might now be eligible for provincial coverage through BC PharmaCare. Diabetics who are on intensive insulin therapy and above the age of two, maybe entitled to the coverage.
The same month, Dexcom announced that people with diabetes below the age of 18 living in Saskatchewan, Canada may now receive provincial coverage for the Dexcom G6 CGM System through Saskatchewan Health.
In May, the company announced that people with type 1 diabetes above the age of two may now receive provincial coverage for the Dexcom G6 CGM System by the Régie de l'Assurance Maladie du Quebec.
Price Performance
Shares of the company have gained 3.8% in the past year compared with the industry’s 12.5% growth and the S&P 500's 34.6% rise.
Image Source: Zacks Investment Research
Zacks Rank & Stock to Consider
Currently, Dexcom carries a Zacks Rank #5 (Strong Sell).
A better-ranked stock from the broader medical space is Veeva Systems Inc. (VEEV - Free Report) .
Veeva Systems’ long-term earnings growth rate is estimated at 15.8%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.